Applicability of fozinopril for correction of basic manifestations of metabolic syndrome in women with arterial hypertension

Terapevticheskii Arkhiv

Volumn 77, Issue 3, 2005, Pages 60-64

  Logacheva, I V ^a   Shustova, Ye N ^a   Morozova, N I ^a  

^a NONE

Author keywords

Arterial hypertension; Fozinopril; Metabolic syndrome; Treatment

Indexed keywords

ANTIOXIDANT; C PEPTIDE; CARBOHYDRATE; FOSINOPRIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PURINE; TRIACYLGLYCEROL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CARBOHYDRATE METABOLISM; CELL MEMBRANE RESISTANCE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE MEMBRANE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPOURICEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MEMBRANE STABILIZATION; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; FOSINOPRIL; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 18244396595     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Ferrannini E., Buzzigoli G., Giorico M. A. Insulin resistance in essential hypertension. N. Engl. J. Med. 1987; 317: 370-377.
2. Penicaud L., Berthault M., Morin J. et al. Rilmenidine normalizes fructose induced insulin resistance and hypertension in rats. J. Hypertens. 1998; 16 (suppl. 3): 45-49.
3. Reaven G. M. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J. Clin. Endocrinol. Metab. 2003; 88: 2399-2403.
4. 1-adrenergic receptors on adipocytes. Med. Hypothes. 2004; 62 (5): 830-838.
5. DeFronzo R. A., Ferrrannini E. Insulin resistance: a multifactorial syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia. Diabetes Care 1991; 14 (1): 1-7.
6. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499-502.
7. Steven M. et al. Homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20 (7): 1087-1099.
8. Stamler J. Epidemic obesity in United States. Arch. Intern. Med. 1998; 150: 1040-1044.
9. Stein P., Blak H. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991; 14 (6): 425-448.
10. Tatti P., Panor M., Byington R. et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21 (4): 597-603.
11. Lithell H. O. Insulin resistance and diabetes in the context of treatment of hypertension. Blood Press. 1998; suppl. 3: 28-31.
12. Caro F. Insulin resistance in obese and nonobese men. J. Clin. Endocrinol. Metab. 1981; 73: 691-695.
13. Febber J. P. et al. Insulin resistance in obesity. Diabetologia 1995; 1: 1220-1228.
14. Feranini E., De Fronzo R. A. The association of hypertension, diabetes and obesity: A review. J. Nephrol. 1989; 1: 3-15.
15. Ruilope L. M., Garcia-Puig J. Hyperuricemia and renal function. Curr. Hypertens. Rep. 2001; 3: 197-202.
16. Garcia-Puig J., Ruilope L. Uric acid as a cardiovascular risk factor in arterial hypertension. J. Hypertens. 1999; 17: 869-872.
17. Aderman M., Cohen H. et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
18. Fang J., Aderman M. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. J. A. M. A. 2000; 283: 2404-2410.
19. Aderman M. Serum uric acid as a cardiovascular risk factor for heart disease. Curr. Hypertens. Rep. 2001; 3: 184-189.